Literature DB >> 26960927

Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?

Melissa Pilewskie1, Maria Karsten2, Julia Radosa2,3, Anne Eaton4, Tari A King2.   

Abstract

BACKGROUND: Sentinel lymph node biopsy (SLNB) is recommended when mastectomy is performed for ductal carcinoma in situ (DCIS). The role of SLNB for women with DCIS who undergo mastectomy following one or more attempts at breast-conserving surgery (BCS) is uncertain. We examined the upgrade rate and SLNB yield in women who converted to mastectomy after one or more attempts at BCS for DCIS.
METHODS: All patients who underwent one or more attempts at BCS prior to conversion to mastectomy with SLNB for DCIS were identified. Margin status as the indication for mastectomy was confirmed, and comparisons were made between patients with/without upgrade on final pathology.
RESULTS: From February 2006 to November 2012, a total of 233 patients underwent completion mastectomy following one or more attempts at BCS for positive/close margins (median age 50 years; range 34-84). The median number of BCS attempts was 1 (range 1-4). Overall, 20 (9 %) patients were upgraded on final pathology; 15 (6 %) stage I, and 5 (3 %) stage II (three micrometastasis, two macrometastasis). In two of five cases with a positive SLN, invasive carcinoma was not identified in the mastectomy specimen. The only factor associated with any upgrade was the presence of micropapillary DCIS (80 vs. 55 %, with and without upgrade; p = 0.03).
CONCLUSION: In this cohort of patients with DCIS who converted to mastectomy for positive/close margins after one or more attempts at BCS, 18 (8 %) would have required second-stage axillary surgery had an SLNB not been performed, and in two (1 %) patients, the SLN provided the only evidence of invasion. These findings support the recommendation for SLNB at the time of completion mastectomy.

Entities:  

Mesh:

Year:  2016        PMID: 26960927      PMCID: PMC4943570          DOI: 10.1245/s10434-016-5145-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  25 in total

Review 1.  Ductal carcinoma in situ of the breast.

Authors:  Harold J Burstein; Kornelia Polyak; Julia S Wong; Susan C Lester; Carolyn M Kaelin
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

2.  Outcome of patients with ductal carcinoma in situ and sentinel node biopsy.

Authors:  T J Meretoja; P S Heikkilä; K Salmenkivi; M H K Leidenius
Journal:  Ann Surg Oncol       Date:  2012-03-07       Impact factor: 5.344

3.  Tumour-positive sentinel node findings in patients with ductal carcinoma in situ.

Authors:  M Leidenius; K Salmenkivi; K von Smitten; P Heikkilä
Journal:  J Surg Oncol       Date:  2006-10-01       Impact factor: 3.454

4.  Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases.

Authors:  Jeong S Han; Kyle H Molberg; Venetia Sarode
Journal:  Breast J       Date:  2011-03-24       Impact factor: 2.431

Review 5.  Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast.

Authors:  B Ansari; S A Ogston; C A Purdie; D J Adamson; D C Brown; A M Thompson
Journal:  Br J Surg       Date:  2008-05       Impact factor: 6.939

6.  Reoperative sentinel lymph node biopsy after previous mastectomy.

Authors:  Amer Karam; Michelle Stempel; Hiram S Cody; Elisa R Port
Journal:  J Am Coll Surg       Date:  2008-07-21       Impact factor: 6.113

7.  Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Authors:  Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

8.  Preoperatively diagnosed ductal carcinoma in situ: risk prediction of invasion and effects on axillary management.

Authors:  Yuya Sato; Takayuki Kinoshita; Junko Suzuki; Kenjiro Jimbo; Sota Asaga; Takashi Hojo; Masayuki Yoshida; Hitoshi Tsuda
Journal:  Breast Cancer       Date:  2015-09-01       Impact factor: 4.239

9.  Ductal carcinoma in situ and sentinel lymph node metastasis in breast cancer.

Authors:  Keiichiro Tada; Akiko Ogiya; Kiyomi Kimura; Hidetomo Morizono; Kotaro Iijima; Yumi Miyagi; Seiichiro Nishimura; Masujiro Makita; Rie Horii; Futoshi Akiyama; Takuji Iwase
Journal:  World J Surg Oncol       Date:  2010-01-27       Impact factor: 2.754

10.  Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ.

Authors:  Tomo Osako; Takuji Iwase; Masaru Ushijima; Rie Horii; Yasuyoshi Fukami; Kiyomi Kimura; Masaaki Matsuura; Futoshi Akiyama
Journal:  Cancer Sci       Date:  2014-03-26       Impact factor: 6.716

View more
  2 in total

1.  Current Trends in the Management of Phyllodes Tumors of the Breast.

Authors:  Taiwo Adesoye; Heather B Neuman; Lee G Wilke; Jessica R Schumacher; Jennifer Steiman; Caprice C Greenberg
Journal:  Ann Surg Oncol       Date:  2016-06-22       Impact factor: 5.344

2.  De-escalating axillary surgery in early-stage breast cancer.

Authors:  Eliza H Hersh; Tari A King
Journal:  Breast       Date:  2021-12-15       Impact factor: 4.254

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.